Entering text into the input field will update the search result below

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Jul. 12, 2022 11:02 AM ETSynlogic, Inc. (SYBX)By: Ravikash, SA News Editor

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


  • Synlogic (NASDAQ:SYBX) said the first healthy volunteer was dosed in a phase 1 trial of its oral therapy SYNB1353 designed to consume an amino acid called methionine for potentially treating homocystinuria (HCU).
  • HCU is rare condition which interferes

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About SYBX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Synlogic, Inc.
AIM ImmunoTech Inc.
Lumos Pharma, Inc.
Evaxion Biotech A/S
ProMIS Neurosciences, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.